

July 18, 2014

Dear Solos Endoscopy, Inc. Shareholders,

I am very pleased to be able to communicate with our loyal shareholders directly and to give you an update on our progress this year.

Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the treatment and management of diseases for over 25 years. The Company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.

Solos Endoscopy has received its ISO 13485:2003 Certification from TUV SUD America. The Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to place the CE Mark on the majority of its endoscopic instruments including the MammoView® devices. The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada. The Certification came at the conclusion of a lengthy Audit with TUV SUD America in 2013. The Audit included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282).

Health Canada's Medical Device Bureau (MDB) completed its evaluation of Solos Endoscopy's instruments and has classified its devices as Class II medical devices. The Medical Device Bureau reviewed the MammoView® Dilator Set, MammoView® Cytology Retrieval Kit, MammoView® Introducer Set, and the Microendoscope Ductoscope. Solos Endoscopy needed to complete the review to apply for Canada's Medical Device License. The Company has delayed the filing of its application while management has been evaluating its multiple options for the Canadian market. The Company is currently working with Spectrum Medical Market Consultants to act as its representative in Canada for its endoscopic instruments including the MammoView® devices.

Solos Endoscopy experienced significant back orders during the first six months of 2014 due to supply issues related to a component manufacturer. As a result of the back orders, the Company's cash flow and sales declined. We are pleased


to inform the shareholders that we have resolved the issues and have resumed shipping to hospitals this past week. We expect sales and cash flow to improve over the next 90 days. In the last six months, fifteen new hospitals have begun to carry Solos Endoscopy instruments. This includes a select number of hospitals who are now carrying the MammoView® product line.

Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease. These products will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. The Company is currently marketing its next generation breast endoscopy system, the MammoView® system, for early breast cancer detection.

Solos Endoscopy, as a public Company, continues to update its shareholders through regular postings on [www.otcmarkets.com](http://www.otcmarkets.com) and through Company press releases. Solos Endoscopy posted a disclosure regarding a notice it received from the Depository Trust Company (DTC) on November 25, 2013. Since that time, Solos Endoscopy's legal counsel has provided DTC several legal opinions to confirm that each of the Subject Securities, including the Notice Securities, were, at the date of deposit at DTC, eligible under the Rules and Procedures of DTC to be deposited for the Services.

To learn more information about the Company and its products visit [www.solosendoscopy.com](http://www.solosendoscopy.com). I want to thank all our loyal shareholders and I look forward to a successful 2014.

Regards,



**Robert Segersten**

*President and CEO*

Solos Endoscopy, Inc.

Certain statements in this document may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this document, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at [www.otcmarkets.com](http://www.otcmarkets.com)). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.